X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AlphaMedix (212Pb-DOTAMTATE) is a targeted alpha therapy, being developed for treatment of adults with unresectable/metastatic, progressive somatostatin receptor expressing gastroenteropancreatic neuroendocrine tumors who are naïve to peptide receptor radionuclide therapy.
Lead Product(s): Alphamedix
Therapeutic Area: Oncology Product Name: AlphaMedix
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Oranomed
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Details:
AlphaMedixTM is a radiolabeled SSTR-targeting therapeutic investigational drug for the treatment of NETs patients. The product consists of SSTR-targeting peptide complex radiolabeled with 212Pb dotamtate that serves as an in vivo generator of alpha-emitting particles.
Lead Product(s): Alphamedix
Therapeutic Area: Oncology Product Name: AlphaMedix
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Oranomed
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Details:
Through the acquisition of Phase 2 program evaluating 225Ac-PSMA I&T, a small molecule targeting prostate specific membrane antigen ("PSMA") expressed on prostate cancers, strengthens the pipeline of innovative targeted alpha therapies.
Lead Product(s): Ac225-PSMA
Therapeutic Area: Oncology Product Name: Ac225-PSMA
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Fusion Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 15, 2023
Details:
The proceeds of the financing will be applied to developing RadioMedix’s flagship radiopharmaceutical AlphaMedix™, a lead-212 (Pb212) labelled somatostatin analogue TAT agent for the treatment of metastatic or inoperable somatostatin expressing neuroendocrine tumors.
Lead Product(s): Alphamedix
Therapeutic Area: Oncology Product Name: AlphaMedix
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Portland Investment Counsel Inc.
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing October 07, 2022
Details:
This strategic partnership substantially supports efforts to have fully compliant 186RNL available by mid-2022 for a potential Phase 2/3 clinical study in adults with recurrent glioblastoma (GBM).
Lead Product(s): Rhenium-186 NanoLiposome
Therapeutic Area: Oncology Product Name: 186RNL
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Plus Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 02, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
